169 related articles for article (PubMed ID: 26669300)
21. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
Cabibbo G; Petta S; Barbara M; Attardo S; Bucci L; Farinati F; Giannini EG; Negrini G; Ciccarese F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Virdone R; Marra F; Mega A; Morisco F; Benvegnù L; Gasbarrini A; Svegliati-Baroni G; Foschi FG; Olivani A; Masotto A; Nardone G; Colecchia A; Persico M; Craxì A; Trevisani F; Cammà C;
J Hepatol; 2017 Jul; 67(1):65-71. PubMed ID: 28192185
[TBL] [Abstract][Full Text] [Related]
22. Epidemiology of HCC in Brazil: incidence and risk factors in a ten-year cohort.
Paranaguá-Vezozzo DC; Ono SK; Alvarado-Mora MV; Farias AQ; Cunha-Silva M; França JI; Alves VA; Sherman M; Carrilho FJ
Ann Hepatol; 2014; 13(4):386-93. PubMed ID: 24927609
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of serum galectin-3 levels in patients with hepatocellular cancer and chronic viral hepatitis.
Ulu M; Alacacioglu A; Yuksel E; Pamukk BO; Bozkaya G; Ari A; Yuksel A; Sop G; Alacacioglu I
Saudi J Gastroenterol; 2015; 21(1):47-50. PubMed ID: 25672239
[TBL] [Abstract][Full Text] [Related]
24. Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: A longitudinal study.
Yen YH; Tsai MC; Wu CK; Chang KC; Hung CH; Chiu KW; Lu SN; Wang JH; Chen CH; Kee KM; Kuo YH; Tseng PL; Lin MT; Huang CM; Lin JT; Hu TH
J Formos Med Assoc; 2018 Sep; 117(9):833-840. PubMed ID: 29089161
[TBL] [Abstract][Full Text] [Related]
25. PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis.
Guyot E; Sutton A; Rufat P; Laguillier C; Mansouri A; Moreau R; Ganne-Carrié N; Beaugrand M; Charnaux N; Trinchet JC; Nahon P
J Hepatol; 2013 Feb; 58(2):312-8. PubMed ID: 23069476
[TBL] [Abstract][Full Text] [Related]
26. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis.
Lim SG; Aung MO; Mak B; Sutedja D; Lee YM; Lee GH; Fernandes M; Low HC; Lai V; Dan YY
J Clin Gastroenterol; 2011 Oct; 45(9):818-23. PubMed ID: 21921845
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis.
Wang Y; Liu YH; Mai SJ; He LJ; Liao YJ; Deng HX; Guan XY; Zeng YX; Kung HF; Xie D
J Gastroenterol Hepatol; 2010 Jun; 25(6):1123-8. PubMed ID: 20594228
[TBL] [Abstract][Full Text] [Related]
29. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy.
Pompili M; Rapaccini GL; Covino M; Pignataro G; Caturelli E; Siena DA; Villani MR; Cedrone A; Gasbarrini G
Cancer; 2001 Jul; 92(1):126-35. PubMed ID: 11443618
[TBL] [Abstract][Full Text] [Related]
31. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment.
Ogawa E; Furusyo N; Nomura H; Dohmen K; Higashi N; Takahashi K; Kawano A; Azuma K; Satoh T; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J;
Aliment Pharmacol Ther; 2018 Jan; 47(1):104-113. PubMed ID: 29035002
[TBL] [Abstract][Full Text] [Related]
32. Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands.
van Meer S; van Erpecum KJ; Sprengers D; Coenraad MJ; Klümpen HJ; Jansen PL; IJzermans JN; Verheij J; van Nieuwkerk CM; Siersema PD; de Man RA
Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):352-9. PubMed ID: 26629867
[TBL] [Abstract][Full Text] [Related]
33. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis.
Giannini EG; Marenco S; Borgonovo G; Savarino V; Farinati F; Del Poggio P; Rapaccini GL; Anna Di Nolfo M; Benvegnù L; Zoli M; Borzio F; Caturelli E; Chiaramonte M; Trevisani F;
Hepatology; 2012 Oct; 56(4):1371-9. PubMed ID: 22535689
[TBL] [Abstract][Full Text] [Related]
34. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
[TBL] [Abstract][Full Text] [Related]
35. Is serum endocan a sensitive biomarker for early recurrence of hepatocellular carcinoma after radiofrequency ablation?
Omar SA; Attia NM; Sheir MI; Amer AS; El Shabrawy MM; Hasan BB
Eur J Gastroenterol Hepatol; 2021 Jul; 33(7):1015-1022. PubMed ID: 33867440
[TBL] [Abstract][Full Text] [Related]
36. Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B.
Hsu YC; Jun T; Huang YT; Yeh ML; Lee CL; Ogawa S; Cho SH; Lin JT; Yu ML; Nguyen MH; Tanaka Y
Aliment Pharmacol Ther; 2018 Nov; 48(10):1128-1137. PubMed ID: 30306612
[TBL] [Abstract][Full Text] [Related]
37. Outcome of 67 patients with hepatocellular cancer detected during screening of 1125 patients with chronic hepatitis.
Izzo F; Cremona F; Ruffolo F; Palaia R; Parisi V; Curley SA
Ann Surg; 1998 Apr; 227(4):513-8. PubMed ID: 9563539
[TBL] [Abstract][Full Text] [Related]
38. Skeletal muscle fat deposition is associated with hepatocellular carcinoma development in patients with chronic liver disease.
Tachi Y; Kozuka A; Hirai T; Kojima Y; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
Nutrition; 2018 Oct; 54():83-88. PubMed ID: 29753174
[TBL] [Abstract][Full Text] [Related]
39. Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis.
Yang JD; Mohamed HA; Cvinar JL; Gores GJ; Roberts LR; Kim WR
Am J Gastroenterol; 2016 Nov; 111(11):1573-1580. PubMed ID: 27527741
[TBL] [Abstract][Full Text] [Related]
40. Natural history of chronic hepatitis B REVEALed.
Chen CJ; Yang HI
J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
